Second Sight Medical Products Inc  

(Public, NASDAQ:EYES)   Watch this stock  
Find more results for eyes
-0.38 (-3.00%)
Real-time:   2:45PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.40 - 12.91
52 week 8.05 - 24.02
Open 12.81
Vol / Avg. 174,107.00/2.62M
Mkt cap 446.06M
P/E     -
Div/yield     -
EPS -0.80
Shares 35.34M
Beta     -
Inst. own 16%
Mar 11, 2015
Q4 2014 Second Sight Medical Products Inc Earnings Call
Mar 11, 2015
Q4 2014 Second Sight Medical Products Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1254.34% -1467.73%
Operating margin -926.94% -1150.05%
EBITD margin - -1129.88%
Return on average assets -282.89% -222.29%
Return on average equity - -
Employees 126 -
CDP Score - -


12744 San Fernando Road, Bldg. 3
SYLMAR, CA 91342
United States - Map
+1-818-8335000 (Phone)
+1-818-8335067 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company�s product, The Argus II Retinal Prosthesis System (Argus II) treats outer retinal degenerations, such as retinitis pigmentosa (RP).It restores functional vision for people suffering from blindness. The Argus II System is approved in the United States by the Food & Drug Administration (FDA) and European Economic Area (CE Mark) and is available in some European countries. As of November 14, 2014, the Company�s Argus II System was implanted in about 90 patients in the United States, Canada, France, Italy, Germany, the Netherlands, Saudi Arabia, Spain, Switzerland and the United Kingdom. The Company is also developing another product for cortical stimulation, known as the Orion I visual prosthesis, to treat nearly all forms of blindness.

Officers and directors

Alfred E. Mann Independent Chairman of the Board and Founder
Age: 88
Bio & Compensation  - Reuters
Robert J Greenberg M.D., Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Thomas B. Miller Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Edward David Randolph Vice President - Manufacturing
Age: 56
Bio & Compensation  - Reuters
Anne-Marie Juliette Ripley Vice President - Clinical and Regulatory Affairs
Age: 44
Bio & Compensation  - Reuters
Brian Vernon Mech Vice President - Business Development
Age: 46
Bio & Compensation  - Reuters
Gregoire Cosendai Vice President - European Operations
Age: 42
Bio & Compensation  - Reuters
Aaron Mendelsohn Director
Age: 63
Bio & Compensation  - Reuters
William J. Link Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Gregg Williams Independent Director
Age: 55
Bio & Compensation  - Reuters